Alzamend Neuro regains Nasdaq listing compliance after meeting stockholders’ equity rule

By Public Technologies
  • Alzamend Neuro regained compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity, closing a continued-listing deficiency matter.
  • Nasdaq’s Sept. 14 notice cited $5.8 million of stockholders’ equity in the Form 10-Q for the quarter ended July 31, 2026.
  • The company had faced a Nasdaq deficiency notice on March 20, 2026, then received an extension to Sept. 16, 2026 to cure it.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609160800PR_NEWS_USPR_____SF49412) on September 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk